WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immune-based products, today announced that President and CEO Lewis H. Bender would be speaking on a CEO Panel titled: Raising Capital in the Current Market during the Immuno-Oncology 360° conference at the Roosevelt Hotel in New York City, NY February 7-9, 2018. IO360 aims to provide a comprehensive program encompassing all facets of IO including discovery, business development, finance, and emerging trends. Mr. Bender’s panel discussion is on February 9, 2018 at 1:45PM.
In addition, Mr. Bender will make a corporate presentation and provide an update on the company’s clinical trial of lead drug, INT230-6, on Monday February 12 at 11:15AM in the Brecht room during the 20th annual BIO CEO & Investor Conference being held at the New York Marriott Marquis hotel in New York City, NY February 12-13.
INT230-6 is a novel, anti-cancer drug for direct intratumoral injection. The product contains potent anti-cancer agents that disperse throughout tumors and diffuse into cancer cells. In preclinical studies INT230-6 eradicated tumors by a combination of direct tumor kill coupled with recruitment of dendritic cells to the tumor micro-environment that stimulated anti-cancer T-cell activation. INT230-6 provides complete responder animals with long-term, durable protection from multiple re-inoculations of the initial cancer and resistance to other cancers. INT230-6 is being evaluated in clinical study, IT-01, www.clinicaltrials.gov (NCT#03058289).
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to greatly extend the lives of patients with cancer. Intensity Therapeutics is pioneering a new immune-based approach to treat cancer. The Company uses its DfuseRxSM platform technology to create new drug formulations that disperse throughout a tumor and diffuse into cancer cells. Drug products created using the technology are capable of attenuating (killing) a tumor in a manner that allows for the adaptive immune system to recognize the cancer and attack distal tumors and micrometastases. Further information can be found at www.intensitytherapeutics.com.
This press release contains forward-looking statements regarding Intensity Therapeutics’ plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.